Vidyya Medical News Service
*
Volume 5 Issue 143 Published - 14:00 UTC 08:00 EST 23-May-2003 Next Update - 14:00 UTC 08:00 EST 24-May-2003
little clear gif used for spacer
.
*

Close look at cancer rates for racial and ethnic groups reveals significant differences
A National Institutes of Health working group defined health disparities as differences in the incidence, prevalence, mortality, and burden of cancer and related adverse health conditions that exist among specific population groups in the United States. These population groups may be characterized by gender, age, ethnicity, education, income, social class, disability, geographic location, sexual orientation.  more

*
Are health-related exclusions keeping too many elderly patients out of cancer trials?
Although most new cases of cancer occur in people aged 65 and over, studies have shown that relatively few people in this age group enroll in clinical trials of new cancer treatments. A new study says requirements that participants in cancer clinical trials be free of other health problems disqualify too many older people from taking part. more

 


*
Number of babies born with gastroschisis, an uncommon but life-threatening birth defect, growing in the U.S.
Gastroschisis, an uncommon but life-threatening birth defect in which babies are born with their intestines outside their abdomens, increased markedly in North Carolina and the rest of the United States in the late 1990s, according to a new University of North Carolina at Chapel Hill study.  more

*
Health care costs deplete the life savings of the retired. Best advice: Stay healthy
People have one more reason to stay healthy as they grow older: holding onto their retirement savings. A new study, led by a researcher at Ohio State University, is the first to contrast how health affects the wealth of elderly married couples versus single or widowed seniors. Healthy people are 6 to 7 percent more likely not to lose a significant portion of their savings, the study showed.  more

*
FDA approves Gleevec for pediatric leukemia treatment
The Food and Drug Administration (FDA) today announced the approval of Gleevec (imatinib mesylate) tablets for the treatment of pediatric patients with Philadelphia chromosome positive(Ph+)chronic myeloid leukemia (CML) in chronic phase a rare, life-threatening form of cancer that accounts for approximately two percent of all leukemias in children.  more

 
little clear gif used for a space